IL6 and neoplasm: It is important to note that clinical trials of EOC patients treated with the VEGF inhibitor aflibercept revealed more reduced survival rates in patients harboring high levels of circulating IL-6, indicating that IL-6/STAT3 activation in tumor cells may provide a survival gain during anti-VEGF treatment [80].